Fixed ratio combinations GLP-1RA and basal insulin: literature review

The progressive nature of type 2 diabetes mellitus leads to the need for insulin therapy in a significant proportion of patients. Very often start of insulin therapy in type 2 diabetes mellitus (T2DM) is associated with weight gain and a significant increase of hypoglycemia’s risk. However, innovative options, such as fixed ratio combinations of glucagon-like peptide 1 receptor agonists (GLP-1RA) and basal insulin, minimize weight gain and hypoglycemia risks and allow a greater proportion of patients to achieve individual glycemic control goals without compromising safety parameters. This review includes a description of the randomized clinical trials, as well as the results of real clinical practice of the use of two currently existing fixed ration combinations of GLP-1RA and basal insulin — iDegLira and iGlarLixi.

1. Kahn SE. The importance of b-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047-4058. doi: https://doi.org/10.1210/jcem.86.9.7713

2. Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY (11th edition). Diabetes mellitus. 2023;26(2S):1-231. (In Russ.). doi: https://doi.org/10.14341/DM13042

3. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. doi: https://doi.org/10.2337/dci22-0034

4. Mauricio D, Meneghini L, Seufert J, et al. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017;19(8):1155-1164. doi: https://doi.org/10.1111/dom.12927

5. Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411-3417. doi: https://doi.org/10.2337/dc13-0331

6. Santos Cavaiola T, Kiriakov Y, Reid T. Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables. Clin Ther. 2019;41(2):352-367. doi: https://doi.org/10.1016/j.clinthera.2018.11.015

7. Anyanwagu U, Mamza J, Gordon J, et al. Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data. Diabet Med. 2017;34(12):1728-1736. doi: https://doi.org/10.1111/dme.13518

8. Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682-9. doi: https://doi.org/10.1111/j.1464-5491.2012.03605.x

9. Forst T, Choudhary P, Schneider D, Linetzky B, Pozzilli P. A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes. Diabetes Metab Res Rev. 2021;37(6):e3418. doi: https://doi.org/10.1002/dmrr.3418

10. Blonde L, Anderson JE, Chava P, Dendy JA. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Curr Med Res Opin. 2019;35(5):793-804. doi: https://doi.org/10.1080/03007995.2018.1541790

11. Tyurenkov IN, Bakulin DA, Kurkin DV, Volotova EV. Neuroprotective properties of incretin mimetics in brain ischemia and neurodegenerative diseases. Problemy endocrinologii. 2017;63:(1):58-67. (In Russ.). doi: https://doi.org/10.14341/probl201763149-58

12. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384(9961):2228-34. doi: https://doi.org/10.1016/S0140-6736(14)61335-0

13. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-57. doi: https://doi.org/10.1053/j.gastro.2007.03.054

14. Niswender KD. Basal insulin: beyond glycemia. Postgrad Med. 2011;123(4):27-37. doi: https://doi.org/10.3810/pgm.2011.07.2301

15. Ferrannini E, Niemoeller E, Dex T, et al. Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes. Diabetes Obes Metab. 2022;24(6):1159-1165. doi: https://doi.org/10.1111/dom.14688

16. Rosenstock J, Aronson R, Grunberger G, et al. LixiLan-O Trial Investigators. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care. 2016;39(11):2026-2035. doi: https://doi.org/10.2337/dc16-0917

17. Aroda VR, Rosenstock J, Wysham C, et al. LixiLan-L Trial Investigators. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care. 2016;39(11):1972-1980. doi: https://doi.org/10.2337/dc16-1495

18. Blonde L, Rosenstock J, Del Prato S, et al. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes Care. 2019;42(11):2108-2116. doi: https://doi.org/10.2337/dc19-1357

19. Del Prato S, Frias JP, Blonde L, et al. Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial. Diabetes Obes Metab. 2020;22(9):1567-1576. doi: https://doi.org/10.1111/dom.14068

20. McCrimmon RJ, Al Sifri S, Emral R, et al. SoliMix Trial investigators. Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial. Diabetes Obes Metab. 2021;23(6):1221-1231. doi: https://doi.org/10.1111/dom.14354

21. Polonsky WH, Giorgino F, Rosenstock J, et al. Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial. Diabetes Obes Metab. 2022;24(12):2364-2372. doi: https://doi.org/10.1111/dom.14822

22. Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885-893. doi: https://doi.org/10.1016/S2213-8587(14)70174-3

23. Buse JB, Vilsbøll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926-2933. doi: https://doi.org/10.2337/dc14-0785

24. Linjawi S, Bode BW, Chaykin LB, et al. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Ther. 2017;8(1):101-114. doi: https://doi.org/10.1007/s13300-016-0218-3

25. Rodbard HW, Bode BW, Harris SB, et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. Diabet Med. 2017;34(2):189-196. doi: https://doi.org/10.1111/dme.13256

26. Lingvay I, Pérez Manghi F, García-Hernández P, et al. DUAL V Investigators. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. JAMA. 2016;315(9):898-907. doi: https://doi.org/10.1001/jama.2016.1252

27. Harris SB, Kocsis G, Prager R, et al. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab. 2017;19(6):858-865. doi: https://doi.org/10.1111/dom.12892

28. Billings LK, Agner BFR, Altuntas Y, et al. The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial. Journal of Diabetes Science and Technology. 2021;15(3):636-645. doi: https://doi.org/10.1177/1932296820906888

29. Aroda VR, González-Galvez G, Grøn R, et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):596-605. doi: https://doi.org/10.1016/S2213-8587(19)30184-6

30. Philis-Tsimikas A, Billings LK, Busch R, et al. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019;21(6):1399-1408. doi: https://doi.org/10.1111/dom.13666

31. King AB, Philis-Tsimikas A, Kilpatrick ES, Langbakke IH, Begtrup K, Vilsbøll T. A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges. Diabetes Technol Ther. 2017;19(4):255-264. doi: https://doi.org/10.1089/dia.2016.0405

32. Kawaguchi Y, Miyamoto S, Hajika Y, et al. Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM. Adv Ther. 2022;39(6):2688-2700. doi: https://doi.org/10.1007/s12325-022-02138-w

33. Candido R, Modugno M, Larosa M, et al. Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study. Diabetes Ther. 2023;14(1):77-92. doi: https://doi.org/10.1007/s13300-022-01328-7

34. Haluzík M, Seufert J, Guja C, et al. Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis. Diabetes Ther. 2023;14(4):639-652. doi: https://doi.org/10.1007/s13300-023-01375-8

35. Antsiferov MB, Demidov NA, Balberova MA, Safronova TI, Mishra OA, Magomedova SG. Real world effectiveness of fixed combination of glargine 100 U/ml and lixisenatide therapy in outpatients with type 2 diabetes: a retrospective cohort study SOLO. Diabetes mellitus. 2022;25(2):112-119. (In Russ.). doi: https://doi.org/10.14341/DM12809

36. Kis JT, Nagy G, Kovacs G. Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes. Diabetes Ther. 2021;12(9):2517-2529. doi: https://doi.org/10.1007/s13300-021-01128-5

37. Bala C, Cerghizan A, Mihai BM, et al. Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro). BMJ Open. 2022;12(5):e060852. doi: https://doi.org/10.1136/bmjopen-2022-060852

38. Lajara R, Heller C, Pantalone KM, et al. iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study. Diabetes Obes Metab. 2023;25(5):1249-1260. doi: https://doi.org/10.1111/dom.14974

39. Bilic-Curcic I, Cigrovski Berkovic M, Bozek T, et al. Comparative efficacy and safety of two fixed ratio combinations in type 2 diabetes mellitus patients previously poorly controlled on different insulin regimens: a multi-centric observational study. Eur Rev Med Pharmacol Sci. 2022;26(8):2782-2793. doi: https://doi.org/10.26355/eurrev_202204_28608

40. Persano M, Nollino L, Sambataro M, et al. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy. Eur Rev Med Pharmacol Sci. 2021;25(2):923-931. doi: https://doi.org/10.26355/eurrev_202101_24661

41. Szépkúti S, Bandur S, Kovács G, et al. Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study. BMC Endocr Disord. 2022;22(1):229. doi: https://doi.org/10.1186/s12902-022-01139-8

42. Di Loreto C, Celleno R, Piastrella L, Del Sandak P. IDegLira fixed-ratio combination in the real world: a retrospective observational single-center Italian experience. Eur Rev Med Pharmacol Sci. 2020;24(20):10671-10679. doi: https://doi.org/10.26355/eurrev_202010_23425

43. Egede LE, Bogdanov A, Fischer L, et al. Glycemic Control Among Patients Newly Prescribed IDegLira Across Prior Therapy Group in US Real-World Practice. Diabetes Ther. 2020;11(7):1579-1589. doi: https://doi.org/10.1007/s13300-020-00850-w